Fraxiparin solution for injections syringe 0.4m (3800 IU/0.4 ml.) №10


Manufacturer: France

Treatment of thromboembolic complications.



Fraxiparin 0.4m Composition
active substance: calcium nadroparin;

1 ml 9500 anti-Xa nadroparin calcium;

1 pre-filled syringe (0.4 ml) contains 3800 anti-Xa nadroparin calcium;

excipients: calcium hydroxide solution (or diluted hydrochloric acid), water for injection.

Fraxiparin 0.4m Dosage form

Basic physical and chemical properties: transparent or slightly opalescent, colorless or light yellow solution, practically does not contain visible particles – at the time of release;

from transparent to slightly opalescent, colorless or light yellow or slightly brown or slightly dark yellow solution, practically free of visible particles – at the end of the shelf life.

Fraxiparin 0.4m Pharmacotherapeutic group
Antithrombotic agents. Heparin group. ATX code B01A B06.

Nadroparin is a low molecular weight heparin (LMWH) in which the antithrombotic activity and anticoagulant activity of standard heparins are not related. It has a higher anti-Xa activity than anti-IIa, or antithrombin activity.

Prevention of thromboembolic complications, namely:

In patients with acute diseases (such as acute heart failure, respiratory failure, severe infections or rheumatic diseases) and decreased motor activity who have a high risk of thromboembolic complications;

Venous thromboembolic disease in surgical interventions accompanied by a moderate and high risk of complications.

Prevention of blood clotting in the extracorporeal circulation during hemodialysis (sessions, usually lasting ≤ 4 hours).

Deep vein thrombosis treatment.

Treatment of unstable angina pectoris and acute myocardial infarction (AMI) without pathological Q wave on the ECG in combination with acetylsalicylic acid.

Nadroparin is contraindicated in the case of:

hypersensitivity to nadroparin or any of the excipients;

severe heparin type II thrombocytopenia caused by unfractionated heparin or low molecular weight heparin, in history, as well as nadroparin-induced thrombocytopenia in history;

episodes of bleeding or a tendency to bleeding associated with hemostasis disorders (DIC may be an exception to this rule, if not associated with heparin treatment);

organic lesions with a risk of bleeding (for example, an active ulcer);

acute disorders of cerebral circulation by hemorrhagic type;